Gossamer Bio (GOSS) Investor Investigation: Levi & Korsinsky Announces Inquiry

New York – Levi & Korsinsky, LLP has launched an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) alleging potential violations of federal securities laws, the firm announced Monday.

The investigation centers on the company’s Phase 3 PROSERA study of seralutinib, a drug candidate for pulmonary arterial hypertension. Gossamer Bio had publicly stated that the patient population enrolled in the study was well-suited to demonstrate a positive treatment effect. However, the trial failed to achieve its primary efficacy endpoint, despite reaching its planned enrollment target.

During a Q1 2025 earnings call on May 15, 2025, CEO Faheem Hasnain expressed strong confidence in the trial’s prospects, stating that baseline patient characteristics were “precisely what we have targeted” and that the company was “more optimistic than ever about the likelihood of achieving positive results.” Management also claimed “over 90% power given the sample size,” according to a press release issued by Levi & Korsinsky.

The PROSERA study’s results, delivered in February 2026, showed a p-value of 0.032, falling short of the pre-specified significance threshold of 0.025. Levi & Korsinsky is now investigating whether Gossamer Bio’s prior statements regarding trial confidence, statistical power, and patient baseline characteristics were accurate.

“Shareholders who purchased GOSS and suffered a loss are encouraged to submit their information,” Levi & Korsinsky stated in a release. Investors seeking to explore potential recovery options under federal securities laws are encouraged to contact Joseph E. Levi, Esq. At [email protected] or (212) 363-7500.

Levi & Korsinsky has a track record of securing settlements for shareholders in securities litigation, and has been ranked among the top firms in the United States by ISS Securities Class Action Services for seven consecutive years. The firm states it has secured “hundreds of millions of dollars for aggrieved shareholders.”